Related references
Note: Only part of the references are listed.Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease
Entcho Klenske et al.
JOURNAL OF CROHNS & COLITIS (2019)
Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breasffeeding on Infections and Development
Rebecca Matro et al.
GASTROENTEROLOGY (2018)
Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature
X. Cortes et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease
Adi Lahat et al.
Journal of Crohns & Colitis (2017)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease
Shomron Ben-Horin et al.
JOURNAL OF CROHNS & COLITIS (2011)
Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin
Patricia Palmeira et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2009)
Share Paper
